You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,956,822

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,956,822

Title:	Method for predicting the response to HER2-directed therapy
Abstract:	This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
Inventor(s):	Bacus; Sarah S. (Hinsdale, IL), Smith; Bradley L. (Marblehead, MA)
Assignee:	Ventana Medical Systems, Inc. (Tucson, AZ) Cell Signaling Technology, Inc. (Beverly, MA)
Application Number:	13/945,568
Patent Claims:	1. A method for identifying a breast tumor that has previously been treated with at least one chemotherapeutic as likely to respond to trastuzumab, comprising: measuring in a sample obtained from the breast tumor: a) expression of epidermal growth factor receptor (EGFR) polypeptide; and b) phosphorylation of extracellular signal-regulated kinase (ERK) polypeptide, wherein phosphorylation of ERK polypeptide is measured using an antibody specific for an epitope comprising a phosphorylated threonine at position 202 of SEQ ID NO: 3, a phosphorylated tyrosine at position 204 of SEQ ID NO: 3, or a combination thereof; identifying the breast tumor as a breast tumor likely to respond to trastuzumab, if the breast tumor is positive for EGFR polypeptide expression and negative for phosphorylation of ERK polypeptide; and administering trastuzumab to the subject from which the breast tumor sample was obtained if the breast tumor is positive for EGFR polypeptide expression and negative for phosphorylation of ERK polypeptide. 2. The method of claim 1, wherein the sample is a biopsy sample. 3. The method of claim 2, wherein the biopsy sample is a paraffin-embedded sample. 4. The method of claim 1, further comprising identifying the breast tumor as not likely to respond to trastuzumab if the breast tumor is negative for EGFR polypeptide expression and positive for phosphorylation of ERK polypeptide. 5. The method of claim 1, wherein the chemotherapeutic comprises cisplatin, doxorubicin, or taxol.

Details for Patent 8,956,822

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2022-04-05
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2022-04-05
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2022-04-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.